Bemarituzumab |
Catalog No.GC65516 |
베마리투주맙은 FGFR2b(FGF 수용체)에 대한 최초의 인간화 IgG1 단일클론항체이다. Bemarituzumab은 섬유아세포 성장 인자가 FGFR2b에 결합하고 활성화하는 것을 차단합니다. 베마리투주맙은 암 연구의 가능성이 있습니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1952272-74-0
Sample solution is provided at 25 µL, 10mM.
Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research[1].
[1]. Daniel Vt Catenacci, et al. Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. Future Oncol. 2019 Jun;15(18):2073-2082.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *